1,200+ Funded Biotech Startups 2026 | Verified Contacts & Funding Data

📅 Last Updated: April 17, 2026 | New startups added weekly

🗺 Part of the Growth List Startup Lists Collection All Startup Lists | US Startup Hubs | By Industry | By Funding Stage

Looking for recently funded biotech startups? This startup database covers 1,200+ verified biotechnology companies with decision-maker contacts and funding details updated weekly. These companies raised over $50 billion globally in 2025, making them among the highest-value targets for B2B sales teams, recruiting firms, and service providers.

Our B2B lead database for biotech startups includes verified founder emails, funding amounts, investor details, and company intelligence — everything your sales team needs for targeted outreach to recently funded companies. The life sciences industry spans pharmaceuticals, agri-tech, diagnostics, synthetic biology, and more, meaning funded companies in this space are actively purchasing tools, services, and talent.

Below, you’ll find 100 recently funded biotech startups with actionable data you can use today.

👉 Jump to the List of 100 Funded Biotech Startups

Quick Stats: Biotech Startup Funding in 2025–2026

• 📍 Major hubs: Boston/Cambridge, San Francisco Bay Area, San Diego, London, Zurich, Singapore
• 💰 Total funding 2025: $50B+ across 3,000+ deals globally
• 🏢 Biotech startups tracked: 1,200+ companies in our database
• 📈 Growth rate: ~14% increase in deal volume year-over-year
• 🎯 Top sub-sectors: Pharmaceuticals (42%), Healthcare tech (21%), AgBio (12%), Diagnostics (10%), Synthetic biology (8%), Other (7%)

Recently Funded Biotech Startups

Biotech Startups at a Glance

• Number of biotech startups in our database: 2,714
• Number of verified email addresses in our database: 3,540
• Number of social profiles in our database: 5,709
• Other data points stored: 39,603
• Total funding raised in 2025: $26,082,983,004
  • Seed: $1,450,989,518
  • Series A: $8,003,083,231
  • Series B: $6,661,487,435
  • Series C: $3,657,250,908
  • Other funding*: $6,310,171,912
• Total funding raised in 2026: $7,403,591,914

*Other funding includes private equity, debt financing, and various other types of capital.

The Biotech Startup Ecosystem in 2026

Biotechnology remains one of the most actively funded startup sectors in the world. Unlike software-first verticals, biotech companies typically require significant capital across multiple rounds — from early seed funding for platform development to Series B and beyond for clinical trials and commercialization. That capital-intensive reality makes them exceptional targets for B2B outreach: once funded, they buy fast.

According to KPMG’s Venture Pulse report, global biotech venture funding has remained resilient despite broader market corrections, with drug discovery, AI-assisted diagnostics, and agricultural biotechnology attracting disproportionate investor attention. The OECD’s biotechnology outlook similarly highlights life sciences as one of the fastest-growing innovation sectors globally, with venture activity concentrated in clinical-stage and platform technology companies. In 2025, the sector saw renewed momentum in late-stage rounds, particularly for companies at the intersection of AI and life sciences.

For B2B sales teams, life sciences companies represent high-intent, high-budget prospects. A company that has just closed a Series A or Series B round in biotech is actively expanding its team, infrastructure, and vendor relationships — typically within 60–90 days of funding announcement. Our broader startup lists collection covers hundreds of verticals, but biotech consistently ranks among the highest-value for conversion-focused sales outreach.

Top Biotech Hubs

Biotech startups cluster around research universities, hospital systems, and established pharma corridors. Understanding the geography helps you target outreach regionally or align with vertical-specific clusters.

Boston/Cambridge, MA is the undisputed global capital of biotech, anchored by Harvard, MIT, and the Broad Institute. The Kendall Square corridor alone houses hundreds of funded companies, with Seed through Series D companies operating in close proximity to their academic partners. Our Boston startups database includes a high concentration of biotech companies across therapeutics, diagnostics, and computational biology.

San Francisco Bay Area remains the second major US hub, particularly for platform biotech companies combining AI with drug discovery. San Francisco and South San Francisco host a dense concentration of funded startups across synthetic biology, genomics, and therapeutic development. See our San Francisco startups database for recently funded companies in this cluster.

San Diego has emerged as a specialist hub for small-molecule drug development and genomics, with a high concentration of Series B and Series C companies scaling toward commercialization.

Internationally, London and the UK have built a strong biotech cluster supported by the NHS and proximity to European regulatory frameworks. Our UK startups database reflects this strength, with biotechnology among the top three sectors by funding volume. Germany (particularly Berlin and Munich) is also notable, as covered in our Germany startups list. Switzerland rounds out the European picture, anchored by Basel’s pharma legacy — see our Switzerland startups database for recently funded companies there.

In Asia-Pacific, India (particularly Bangalore and Hyderabad) and Singapore are fast-growing centers for diagnostics, agri-biotech, and cell/gene therapy manufacturing. Our India startups and Bangalore startups databases include a significant number of funded biotech companies for teams targeting those markets.

Biotech Funding Trends

AI-Driven Drug Discovery is Dominating Early Rounds

The intersection of artificial intelligence and biotech continues to attract the most aggressive early-stage capital. Companies using machine learning to accelerate target identification, predict protein structures, or optimize clinical trial design have commanded outsized valuations at Seed and Series A. According to PitchBook’s life sciences report, AI-assisted biotech companies raised at a median valuation premium of 35% over comparable non-AI peers in 2024–2025. For context, see how this overlaps with our AI startups database — many companies straddle both verticals.

Series B and C Are Rebounding

After a correction in 2023–2024, late-stage funding activity has recovered strongly. Series C startups in biotech are often entering pivotal clinical trials or preparing for regulatory submissions — a stage when external vendors (CROs, CMOs, software platforms, staffing firms) become critical purchasing priorities. The National Venture Capital Association (NVCA) confirmed in its most recent yearbook that life sciences maintains its position as the second-largest sector by US VC investment.

AgBio and Environmental Biotech Growing Fast

Agricultural and environmental biotechnology — covering precision fermentation, soil microbiome treatments, and sustainable materials — have seen significant deal growth. According to AgFunder’s annual report, agri-biotech attracted over $5B in global VC investment in 2024. Companies in this sub-sector often sit across our agriculture startups list as well, making cross-referencing valuable for teams with broad life sciences coverage.

Geography Expanding Beyond Traditional Hubs

While Boston and San Francisco remain dominant, our verified startup contacts database reflects growing deal activity in the UK, Germany, Switzerland, South Korea, and India. The Startup Genome Global Ecosystem Report ranks Singapore, London, and Stockholm among the fastest-rising biotech ecosystems outside North America. Sales teams ignoring international biotech are leaving real pipeline on the table.

Key Investors in Biotech Startups

Understanding who funds startups in this sector helps sales teams time outreach and predict follow-on deal activity. The most active investors in the sector include:

ARCH Venture Partners — a specialist in translational research spinouts, known for backing companies at the earliest stages from academic labs.

Flagship Pioneering — creator of platform biotech companies including Moderna, with a portfolio spanning therapeutics, nutrition, and environmental science.

Third Rock Ventures — focused on building companies from the ground up in oncology, rare disease, and immunology.

Andreessen Horowitz (Bio Fund) — a16z’s dedicated bio fund, particularly active in computational biology and AI-assisted drug discovery. See our Andreessen Horowitz portfolio for a breakdown of their funded companies.

GV (Google Ventures) — active across diagnostics, digital health, and life sciences software.

These investors typically signal a company’s entry into an active growth phase. When you see a biotech startup in our B2B lead database backed by one of these firms, the buying window is typically narrow and immediate. Our startup intelligence resources cover how to use investor signals as part of a broader trigger-based prospecting workflow.

What Makes Funded Life Sciences Companies Different as B2B Targets

Selling to recently funded startups in the life sciences space requires a different approach than selling to SaaS or fintech companies. Understanding the buying dynamics specific to this sector dramatically improves conversion rates.

Longer sales cycles, but higher contract values. A therapeutics company that has just closed a Series B is not making impulsive purchasing decisions. Regulatory requirements, IP considerations, and scientific due diligence mean that procurement timelines are measured in weeks rather than days. However, when deals close, they tend to be larger — multi-year contracts with CROs, CDMOs, and software vendors are common. The right outreach approach accounts for this: lead with credibility and expertise, not urgency.

Decision-makers sit higher in the organization. Unlike software companies where a department manager might sign off on a tool, early-stage life sciences companies make most vendor decisions at the founder, CEO, or Chief Scientific Officer level. This is especially true at Seed and Series A stages, where there is typically no dedicated procurement function. Cold outreach that lands with the right C-suite contact — via a verified startup lead database — bypasses the usual gatekeeping.

Funding stage signals buying intent more than industry. A pre-revenue therapeutics company at Seed stage has very different purchasing needs than a Series C company preparing for a pivotal trial. Seed companies are hiring and building infrastructure. Series A companies are activating vendor relationships and locking in partnerships. Series B and C companies are scaling operations and spending at significantly higher volumes. Mapping your outreach message to stage — not just sector — is the single biggest lever for improving response rates.

The 60–90 day window is real. Data from sales teams using the Growth List funded startup leads database consistently shows that outreach within 60–90 days of a funding announcement delivers 3–5x higher response rates than outreach to the same company six months later. Post-funding, founders are actively taking meetings, building their vendor roster, and making decisions quickly. Past that window, they have typically already chosen their key partners for the current funding period.

Geography still matters for relationship-based verticals. Life sciences is more relationship-driven than most tech sectors. Companies in the Boston/Cambridge cluster often prefer to work with local CROs and consultants at early stages. San Diego companies have established networks within the contract manufacturing ecosystem there. For B2B teams doing account-based outreach, our geographic startup databases — including UK startups, Canada startups, and Australia startups — allow you to filter funded companies by location, matching your team’s regional coverage to the right accounts.

Regulatory milestones create predictable buying events. Unlike pure software companies, life sciences startups have structured regulatory milestones — IND filings, Phase I trial initiation, FDA breakthrough designations — that reliably trigger new purchasing activity. Sales teams that track these milestones alongside funding signals can time outreach with even greater precision. Our startup intelligence resources cover how to build this kind of trigger-based prospecting into your workflow.

Comparing Life Sciences Startup Data Sources

Not all startup databases are built the same way, and for sales teams targeting recently funded companies in life sciences, the differences matter more than in most sectors. Here is how the main options compare.

Crunchbase is the most widely known startup database, with broad coverage across all industries. For life sciences prospecting, its strengths are coverage depth and historical funding data. Its weaknesses are contact accuracy (emails are often outdated or missing) and a lack of recency signals — the platform does not prioritize surfacing companies that just raised in the past 30–60 days. Teams using Crunchbase for outreach typically spend significant time manually verifying contacts and cross-referencing funding dates. See our B2B lead generation tools guide for a full comparison of database options.

PitchBook is the enterprise standard for investor-grade startup intelligence. Its data is comprehensive and well-maintained, but it is priced for institutional use (typically $20,000+ per year) and designed around investor workflows rather than sales prospecting. Decision-maker contact data is available but not the primary feature, and the interface is built for deal research, not bulk outreach.

LinkedIn Sales Navigator provides contact discovery and is strong for relationship mapping, but it has significant limitations for this use case: it does not surface funding signals, it requires manual verification of contact details, and export capabilities are restricted. Building a list of 100 recently funded companies with verified C-suite emails via Sales Navigator takes a full day of manual work.

Specialized funded startup databases like Growth List are built specifically for the sales prospecting workflow. The focus is on recency (companies funded in the last 90 days), verified direct contact information for founders and executives, and funding intelligence that tells you exactly how much was raised, at what stage, and from whom. For teams whose core use case is outreach to recently funded companies, this is a significantly more efficient starting point. Our how to build a startup lead list guide covers the full workflow for combining these sources effectively.

Manual research via TechCrunch and press releases remains a common approach for smaller teams. According to the TOPO Sales Development benchmark report, manual list-building costs sales development reps an average of 15–20 hours per 100 verified contacts. For teams doing this more than once a quarter, the time cost exceeds the cost of a startup lead database subscription.

The right answer for most B2B sales teams targeting this sector is a combination: use a funded startup database as the core source of recently-raised companies with verified contacts, supplement with Crunchbase for background research on specific accounts, and use LinkedIn for relationship mapping once you have identified your target accounts.

Biotech Sub-Sectors to Watch

Biotech is not monolithic. Different sub-sectors have different buying cycles, vendor needs, and decision-maker profiles. The main categories relevant to B2B sales teams:

Pharmaceuticals & Therapeutics — the largest sub-sector by funding volume. Companies here prioritize CRO/CMO partnerships, regulatory consulting, and clinical data management tools. See our pharma startups database for recently funded companies in this space.

Healthcare Diagnostics — a fast-moving space driven by personalized medicine trends. Companies often purchase lab equipment, software platforms, and data analytics tools post-funding. See our healthcare startups list for overlap.

Agricultural Biotechnology — companies developing biological crop protection, soil enhancement, or precision fermentation solutions. Overlaps significantly with our agriculture startups database.

Synthetic Biology & Materials — earlier-stage companies often at Seed or Series A, building platform technologies. High hiring velocity post-funding.

Mental Health & Wellness Biotech — a growing category intersecting neuroscience, psychedelic-assisted therapy research, and wellness technology. See our mental health startups and wellness startups databases for companies active in this space.

Using Biotech Startup Databases for B2B Outreach

Finding recently funded biotech companies manually — through press releases, Crunchbase searches, and LinkedIn lookups — is time-consuming and often incomplete. A comprehensive startup database provides verified contacts, funding details, and decision-maker information updated weekly, removing the research burden from your team.

When evaluating biotech startup lead databases, prioritize:

Data freshness — Weekly updates vs quarterly. Biotech funding moves fast; a company that raised three months ago has often already signed key vendor contracts.

Contact verification — Direct founder and C-suite emails vs generic info@ addresses. Most biotech companies make decisions at the founder or VP level in early stages.

Funding intelligence — Round size, stage, lead investors, and date. These signals tell you where a company is in its buying cycle.

Sub-sector tagging — Filtering by therapeutics vs agbio vs diagnostics lets you route leads to the right rep.

Growth List maintains the most current B2B lead database for sales teams targeting biotech and life sciences startups, with 100s of new funded companies added across all sectors every week.

🗂️ Explore More Startup Lists

This list is part of Growth List’s startup database—the most comprehensive B2B lead resource for sales teams targeting recently funded companies.

Browse related lists:

• By Location: NYC Startups | San Francisco Startups | London Startups | India Startups | All Locations →
• By Industry: AI Startups | FinTech Startups | SaaS Startups | All Industries →
• By Funding Stage: Seed Startups | Series A Startups | Series B Startups | All Stages →

Frequently Asked Questions

You May Also Like…

• Healthcare startups with recent funding
• Pharmaceutical startups with recent funding
• Agriculture startups with recent funding
• AI startups with recent funding
• Mental health startups with recent funding
• Wellness startups with recent funding
• All funded startups database